The Management of a Clinical T1b Renal Tumor in the Presence of a Normal Contralateral Kidney
|
|
- Ashlyn Goodwin
- 8 years ago
- Views:
Transcription
1 Opposing Views The Management of a Clinical T1b Renal Tumor in the Presence of a Normal Contralateral Kidney NEPHRON SPARING SURGERY When a patient is seated in front of you with a6cm contrast enhancing renal mass and a normal contralateral kidney and asks, Doc, what should I do? Should I get the whole kidney taken out or just the tumor? most urologists have a preferred answer. In fact, when presented with identical patient scenarios, including computerized tomography images and a 3-dimensional rendering of the tumor within the kidney, 81% of high volume, academic surgeons recommend a partial nephrectomy (PN) compared to only 30% of surgeons working in different settings. 1 It appears that many patients ultimately undergo a radical (RN) or PN based more on surgeon practice patterns than patient preference or tumor characteristics. However, what if the patient asks, Doc, what is the right thing to do? In this case review of the literature will help our patients get the answers they deserve. We review the data suggesting that PN is often the best choice. For patients with clinical stage T1b tumors, there is little debate that PN yields cancer control outcomes equivalent to those provided by RN. This conclusion is supported by multiple studies comparing cancer specific survival between these 2 treatments, including a phase 3 trial 2 and a meta-analysis that pooled data from multiple studies comprising cases with a diverse range of clinical stages (T1a to T3a). 3 If we can confidently counsel patients about equivalent cancer control, then the next question is whether there are substantive differences in shortterm convalescence and/or complications after PN vs RN. Clearly, there are certain (significant) complications, including postoperative bleeding and urine leak, which are more common with PN. However, while this finding leads many to argue that the overall morbidity and complication risk is greater with PN, 2 recent data suggest that these differences may actually be small and dependent largely on factors such as tumor complexity and surgeon experience. 4,5 While issues around short-term morbidity can be debated, the reality is that a recommendation for elective PN in this group of patients only makes sense if there is a long-term benefit to preserving uninvolved nephrons in the tumor bearing kidney. Criteria with respect to clinical measures of renal function have been met. Multiple studies have consistently identified higher postoperative glomerular filtration rates and, as a consequence, a lower incidence of new onset chronic kidney disease (CKD) among patients with clinical stage T1b tumors treated with PN rather than RN. 2,3,6 Moreover, this better preservation of kidney function is evident even when ischemia time exceeds 20 to 30 minutes. 7 Even more importantly, data suggest that preservation of renal function may translate into better long-term outcomes for patients undergoing nephron sparing surgery. For instance, among medical patients, chronic kidney disease is associated with a graded risk of adverse cardiovascular events and death from any cause, namely, as kidney function worsens, the risk of these unfavorable outcomes increases in synchronicity. 8 However, the unanswered question is whether surgically induced CKD caused by the performance of RN rather than PN has a natural history analogous to that observed with medical CKD. In other words, does better preservation of kidney function via nephron sparing surgery translate into better long-term survival via avoidance of CKD related morbidity and mortality? A definitive answer to this question is not yet available as many of the studies examining longterm survival after PN vs RN provide limited or no data on postoperative kidney function. Nonetheless, captivating data from several observational studies (comprising thousands of patients) indicate that treatment with PN is associated with better longterm survival. In the absence of randomization this survival advantage can be easily dismissed as due to selection bias and/or residual confounding. While this is certainly plausible, at least 2 studies used advanced econometric techniques designed to address such concerns, and both still identified a longterm survival benefit with PN. Weight et al performed a single institution retrospective cohort study of more than 1,000 patients /13/ /0 THE JOURNAL OF UROLOGY Vol. 189, , April by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC. Printed in U.S.A
2 OPPOSING VIEWS 1199 treated with PN or RN for a suspected clinical stage T1b kidney cancer. 9 The 2 important strengths of this study were 1) the investigators implemented a propensity score analysis to better balance measured confounding variables (eg age, comorbidities, tumor size, preoperative renal function) between the treatment groups and 2) availability of granular clinical data allowed specific examination of the relationship between postoperative renal function and long-term survival. The pivotal finding was that postoperative renal function was strongly associated with overall and cardiovascular specific survival. Moreover, postoperative renal function appeared to explain the better survival outcomes for patients treated with PN vs RN. While certainly not definitive, these data begin to clarify a link among nephron sparing surgery, preservation of renal function and longer life. Although it did not include patients with tumors larger than 4 cm, a second relevant study was a population based analysis for which data from SEER (Surveillance, Epidemiology and End Results) were linked with Medicare claims to compare cancer specific and overall survival among patients treated with PN or RN for clinical stage T1a kidney cancer. 10 This study included more than 7,000 patients and comprised an instrumental variable analysis, an approach widely used by economists and other social scientists, to address the issue of residual bias and/or unmeasured confounding (ie unmeasured differences between patients in the PN and RN cohorts). The principal finding was that patients treated with PN had a significantly lower risk of death from any cause. There was no difference in cancer specific mortality between the treatment groups. Although this study did not include patients with clinical stage T1b tumors, its findings, based on methods that can account for unmeasured confounding, motivate continued examination of this question. Standing in contrast to the findings from these large observational studies are the results from a single phase 3 randomized, controlled trial involving only 541 patients, which compared long-term survival after partial vs radical nephrectomy. There was no survival benefit with PN and in the intention-to-treat analysis patients treated with RN actually had better outcomes. 2 While this finding must be acknowledged as potentially practice-changing, it is also true that the EORTC (European Organisation for Research and Treatment of Cancer) trial had several significant shortcomings with respect to its design and implementation. Therefore, we believe that this single negative study, comprised largely of patients with T1a tumors, should not be considered definitive proof that we should abandon elective PN for clinical stage T1b tumors. Ultimately, our field would benefit greatly from a randomized controlled trial that specifically compares a variety of relevant outcomes after PN vs RN for clinical stage T1b tumors. These outcomes would include, among others, postoperative complications, longitudinal renal function, health related quality of life, and cancer specific and overall survival. The findings of such a study would be bolstered significantly if its design and analysis explicitly account for additional factors that influence these outcomes, including surgeon volume and tumor complexity. In the end it may well be that certain patients with clinical stage T1b tumors are best treated with PN, while others should undergo total kidney removal. This decision may appropriately be influenced by the characteristics (eg comorbidity, tumor location) and preferences of the patient, and experience of the surgeon. The availability of such data would represent a major advance toward individualizing surgical treatment for patients with kidney cancer. Until more data are available, however, elective PN should remain an acceptable treatment option for patients with T1b tumors. Christopher J. Weight University of Minnesota Minneapolis, Minnesota David C. Miller University of Michigan Ann Arbor, Michigan RADICAL NEPHRECTOMY Persuasive dogma in our field mandates that partial nephrectomy should be performed when feasible, even in the presence of a normal contralateral kidney. Radical nephrectomy is associated with an increased risk of chronic kidney disease, and current belief suggests that this leads to morbid cardiovascular events and increased mortality rates (part A of figure). While avoiding RN is advisable for small renal masses, 11 what about larger tumors, specifically the clinical T1b (4 to 7 cm) renal mass? A more fundamental question must be answered first. How strong is the evidence that supports the above paradigm? In reality it is based on a series of retrospective studies that are likely contaminated by selection bias. Despite intensive efforts to control for recognizable and unrecognizable confounders through multivariate and other sophisticated analyses, there is no way to eliminate them. A recent meta-analysis of the literature provides the most damning evidence. 4 Kim et al evaluated 35 retrospective studies of PN vs RN comprising more 4,000 patients and based on the pooled analysis reported that PN resulted in 61% risk reduction for develop-
3 1200 OPPOSING VIEWS Conceptual issues related to radical nephrectomy in setting of normal contralateral kidney. A, current dogma presumes strong correlation between CKD related to surgery and adverse outcomes. B, recent data have called into question such relationships, suggesting potential difference between CKD due to medical causes vs that due to surgery. C, randomized trial will be required to define merits and limitations of each approach.
4 OPPOSING VIEWS 1201 ment of severe CKD (p 0.001) and a 19% risk reduction in all cause mortality (p 0.001). However, this meta-analysis also revealed a 29% risk reduction in cancer specific mortality in favor of PN (p 0.002) which is difficult to explain. It is intuitive that PN is not a stronger oncologic intervention than RN. The only reasonable way to explain this result is selection bias, and the underlying selection bias is likely contributing to the other results in favor of PN. How can we reconcile this? The best way to eliminate selection bias, of course, is to perform a randomized clinical trial, which brings us to EORTC In this important trial of patients with small (less than 5.0 cm), solitary, clinically localized renal masses and a normal contralateral kidney 268 were randomized to undergo PN and 273 were randomized to undergo RN. As expected the trial showed an advantage for RN in terms of lower morbidity, while PN provided better renal functional outcomes. Based on the current paradigm, we would have anticipated better overall survival in the PN group, primarily driven by a reduced incidence of cardiovascular deaths. However, the 10- year overall survival was actually better for RN than PN (81% vs 76%, respectively, p 0.03) and cardiovascular deaths were less common in the RN group (20 vs 25). This trial has some flaws and most thought leaders in the field, including the authors, do not want to interpret it literally. However, the important concept that we should take away from EORTC is that it suggests that the functional advantage of PN in the setting of a normal contralateral kidney may not be as great as previously believed. Stated another way, there may be a difference between CKD due to medical causes (CKD-M) vs that due to surgery (CKD-S). Patients with CKD-M due to hypertension, diabetes or other renal impediments continue to have these comorbidities and renal function will progressively decline, eventually placing them at risk for adverse events. 8 However, patients with CKD only after surgery typically do not require further surgery and might stabilize with time. We tested this hypothesis in a series of more than 4,000 patients undergoing either PN or RN, including 1,182 with CKD-M and 927 with CKD-S. We found that patients with CKD-M experienced a mean annual renal function decline of 4.7% compared to only 0.7% for the CKD-S group. 12 Furthermore, survival of patients with CKD-S was similar to patients with no CKD, and substantially better than patients with CKD-M. Further studies are required but our data suggest that patients with CKD-S are much more stable and may not suffer from the increased mortality rates that plague patients with CKD-M. A more comprehensive analysis of renal function outcomes from EORTC is now in progress, with preliminary results demonstrating stable renal function in the PN and RN groups out 10 to 15 years. Taken together, these studies suggest that the renal function advantage of PN in the setting of a normal contralateral kidney may not be as beneficial as previously thought (part B of figure). Where does this leave us in 2013? Clearly there is still an essential role for PN in patients who do not have a contralateral kidney or when preservation of renal function is at a premium. In addition, most small renal tumors (T1a, less than 4.0 cm) have limited oncologic potential and RN represents therapeutic overkill in this setting. The main point of contention relates to patients with clinical T1b/T2a tumors and a normal contralateral kidney. These tumors have increased oncologic potential and in many cases have already replaced a considerable proportion of the nephron mass, leaving less to be saved with PN. These patients should be considered for RN to reduce the potential morbidity of the procedure and provide optimal oncologic outcomes. The favorable long-term outcome for patients undergoing donor nephrectomy also supports selective use of RN as long as it is applied intelligently. In the end, a randomized clinical trial of PN vs RN will be required in this population to provide high level evidence and guide patient counseling (part C of figure). Such a trial will also provide a wealth of information about renal function after surgery which will help us reassess current dogma and place this field on more solid ground heading into the future. Steven C. Campbell Glickman Kidney and Urological Institute Cleveland Clinic Cleveland, Ohio Ithaar H. Derweesh Division of Urology University of California San Diego School of Medicine La Jolla, California Brian R. Lane Division of Urology Spectrum Health Medical Group/Michigan State University College of Human Medicine Grand Rapids, Michigan, and Edward M. Messing University of Rochester School of Medicine Rochester, New York
5 1202 OPPOSING VIEWS REFERENCES 1. Weight CJ, Crispen PL, Breau RH et al: Practicesetting and surgeon characteristics heavily influence the decision to perform partial nephrectomy among American Urological Association surgeons. BJU Int 2012; Epub ahead of print. 2. Van Poppel H, Da Pozzo L, Albrecht W et al: A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011; 59: Kim SP, Thompson RH, Boorjian SA et al: Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol 2012; 188: Kim SP, Leibovich BC, Shah ND et al: The relationship of postoperative complications with inhospital outcomes and costs after renal surgery for kidney cancer. BJU Int 2012; Epub ahead of print. 5. Ellison JS, Montgomery JS, Hafez K S et al: Association of RENAL nephrometry score with outcomes of minimally invasive partial nephrectomy. Int J Urol 2012; Epub ahead of print. 6. Weight CJ, Larson BT, Gao T et al: Elective partial nephrectomy in patients with clinical T1b renal tumors is associated with improved overall survival. Urology 2010; 76: Lane BR, Fergany AF, Weight CJ et al: Renal functional outcomes after partial nephrectomy with extended ischemic intervals are better than after radical nephrectomy. J Urol 2010; 184: Go AS, Chertow GM, Fan D et al: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New Engl J Med 2004; 351: Weight CJ, Larson BT, Fergany AF et al: Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized ct1b renal masses. J Urol 2010; 183: Tan HJ, Norton EC, Ye Z et al: Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. JAMA 2012; 307: Campbell SC, Novick AC, Belldegrun A et al: Guideline for management of the clinical T1 renal mass. J Urol 2009; 182: Lane BR, Campbell SC, Demirjian S et al: Surgically induced chronic kidney disease may be associated with lesser risk of progression and mortality than medical chronic kidney disease. J Urol 2012; Epub ahead of print.
KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA
KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,
More informationFunctional Recovery After Partial Nephrectomy: Effects of Volume Loss and Ischemic Injury
Functional Recovery After Partial Nephrectomy: Effects of Volume Loss and Ischemic Injury Matthew N. Simmons,* Shahab P. Hillyer, Byron H. Lee, Amr F. Fergany, Jihad Kaouk and Steven C. Campbell From the
More informationNEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
More informationPreservation and Incorporation of Valuable Endoscopic Innovations (PIVI)
Preservation and Incorporation of Valuable Endoscopic Innovations (PIVI) The American Society for Gastrointestinal Endoscopy PIVI on Endoscopic Bariatric Procedures (short form) Please see related White
More informationClinical Practice Assessment Robotic surgery
Clinical Practice Assessment Robotic surgery Background: Surgery is by nature invasive. Efforts have been made over time to reduce complications and the trauma inherently associated with surgery through
More informationTreatment and Surveillance of Non- Muscle Invasive Bladder Cancer
Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer David Josephson, MD FACS Fellowship Director, Urologic Oncology and Robotic Surgery Program Staging Most important in risk assessment and
More informationObjectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
More informationCONTEMPORARY MANAGEMENT OF RENAL ANGIOMYOLIPOMA
CONTEMPORARY MANAGEMENT OF RENAL ANGIOMYOLIPOMA Stephen A. Boorjian, MD Professor of Urology Vice Chair of Research Director, Urologic Oncology Fellowship Department of Urology Mayo Clinic, Rochester,
More informationTreatment of Low Risk MDS. Overview. Myelodysplastic Syndromes (MDS)
Overview Amy Davidoff, Ph.D., M.S. Associate Professor Pharmaceutical Health Services Research Department, Peter Lamy Center on Drug Therapy and Aging University of Maryland School of Pharmacy Clinical
More informationHow can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris
How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris Pros and cons of registers Prospective randomised trials constitute the cornerstone of "evidence-based" medicine, and they therefore
More informationStage IV Renal Cell Carcinoma. Changing Management in A Comprehensive Community Cancer Center. Susquehanna Health Cancer Center
Stage IV Renal Cell Carcinoma Changing Management in A Comprehensive Community Cancer Center Susquehanna Health Cancer Center 2000 2009 Warren L. Robinson, MD, FACP January 27, 2014 Introduction 65,150
More informationSecondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer
Copyright E 2007 Journal of Insurance Medicine J Insur Med 2007;39:242 250 MORTALITY Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer David Wesley, MD; Hugh
More informationThe PLCO Trial Not a comparison of Screening vs no Screening
PSA Screening: Science, Politics and Uncertainty David F. Penson, MD, MPH Hamilton and Howd Chair of Urologic Oncology Professor and Chair, Department of Urologic Surgery Director, Center for Surgical
More informationElectronic health records to study population health: opportunities and challenges
Electronic health records to study population health: opportunities and challenges Caroline A. Thompson, PhD, MPH Assistant Professor of Epidemiology San Diego State University Caroline.Thompson@mail.sdsu.edu
More informationHEALTH CARE COSTS 11
2 Health Care Costs Chronic health problems account for a substantial part of health care costs. Annually, three diseases, cardiovascular disease (including stroke), cancer, and diabetes, make up about
More informationJohn E. O Toole, Marjorie C. Wang, and Michael G. Kaiser
Hypothermia and Human Spinal Cord Injury: Updated Position Statement and Evidence Based Recommendations from the AANS/CNS Joint Sections on Disorders of the Spine & Peripheral Nerves and Neurotrauma &
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationGuidelines for Management of Renal Cancer
Guidelines for Management of Renal Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Section 5 updated bullets 5.3 and 5.4 Section 6 updated
More informationMetastatic Renal Cell Carcinoma Risk According to Tumor Size
Metastatic Renal Cell Carcinoma Risk According to Tumor Size R. Houston Thompson, Jennifer R. Hill, Yuriy Babayev, Angel Cronin, Matt Kaag, Shilajit Kundu, Melanie Bernstein, Jonathan Coleman, Guido Dalbagni,
More informationProstate Cancer Screening in Taiwan: a must
Prostate Cancer Screening in Taiwan: a must 吳 俊 德 基 隆 長 庚 醫 院 台 灣 醫 學 會 105 th What is the PSA test? The blood level of PSA is often elevated in men with prostate cancer, and the PSA test was originally
More informationThe Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery
The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery Michael E. Farkouh, MD, MSc Peter Munk Chair in Multinational Clinical Trials Director, Heart and Stroke
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationECG may be indicated for patients with cardiovascular risk factors
eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,
More informationOncological outcome of surgical treatment in 336 patients with renal cell carcinoma
窑 Original Article 窑 Chinese Journal of Cancer Oncological outcome of surgical treatment in 336 patients with renal cell carcinoma Zhi Ling Zhang,2, Yong Hong Li,2, Yong Hong Xiong 3, Guo Liang Hou,2,
More informationThe PSA Controversy: Defining It, Discussing It, and Coping With It
The PSA Controversy: Defining It, Discussing It, and Coping With It 11 TH ANNUAL SYMPOSIUM ON MEN S HEALTH June 12, 2013 The PSA Controversy Defining It, Discussing It and Coping With It As of May 2012,
More informationHow To Know If Low Protein Diet Is Beneficial For Kidney Health
Protein Intake and Diabetic Kidney Disease Robert C. Stanton Joslin Diabetes Center 1/Serum Creatinine Plot Low Protein Protects in Renal Ablation Model 24% Protein Diet 6% Protein Diet Right Nephrectomy
More informationUpdate on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward
Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward 33 rd Annual Internal Medicine Update December 5, 2015 Ryan C. Hedgepeth, MD, MS Chief of
More informationBACKGROUND. Evidence exists to suggest a pattern of increasing early diagnosis
78 Renal Cell Cancer Stage Migration Analysis of the National Cancer Data Base Christopher J. Kane, MD 1,2 Katherine Mallin, PhD 3 Jamie Ritchey, MPH 3 Matthew R. Cooperberg, MD, MPH 4 Peter R. Carroll,
More informationHow TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer
How TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer Jeffrey S Tobias, Jayant S Vaidya, Frederik Wenz and Michael Baum, University College Hospital, London, UK - on behalf
More informationUsing 'Big Data' to Estimate Benefits and Harms of Healthcare Interventions
Using 'Big Data' to Estimate Benefits and Harms of Healthcare Interventions Experience with ICES and CNODES DAVID HENRY, PROFESSOR OF HEALTH SYSTEMS DATA, UNIVERSITY OF TORONTO, SENIOR SCIENTIST, INSTITUTE
More informationWith Big Data Comes Big Responsibility
With Big Data Comes Big Responsibility Using health care data to emulate randomized trials when randomized trials are not available Miguel A. Hernán Departments of Epidemiology and Biostatistics Harvard
More informationKidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
More informationMANITOBA DIABETES FORUM REPORT Prepared by the Life Science Association of Manitoba September 13, 2012, University of Winnipeg
MANITOBA DIABETES FORUM REPORT Prepared by the Life Science Association of Manitoba September 13, 2012, University of Winnipeg Background Diabetes In Manitoba Manitoba is faced with profound health and
More informationMortality Assessment Technology: A New Tool for Life Insurance Underwriting
Mortality Assessment Technology: A New Tool for Life Insurance Underwriting Guizhou Hu, MD, PhD BioSignia, Inc, Durham, North Carolina Abstract The ability to more accurately predict chronic disease morbidity
More informationJanuary 18, 2013. Dear Dr. Schafer,
Medical School Center for Healthcare Outcomes & Policy Bldg 520, Room 31658 2800 Plymouth Rd, SPC 2800 Ann Arbor, Ml48109 (734) 998-7470 (734) 998-7473 fax January 18, 2013 Jyme H. Schafer, MD, MPH Director,
More informationProstate cancer. Christopher Eden. The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing.
Prostate cancer Christopher Eden The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing. Screening Screening men for PCa (prostate cancer) using PSA (Prostate Specific Antigen blood
More informationNeal Rouzier responds to the JAMA article on Men and Testosterone
Neal Rouzier responds to the JAMA article on Men and Testosterone On the first day the JAMA article was released I received 500 emails from physicians and patients requesting my opinion of the article
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationSIOG Guidelines Update 2014 Prostate Cancer. Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon
SIOG Guidelines Update 2014 Prostate Cancer Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, Dickinson L, Efstathiou
More information4/8/13. Pre-test Audience Response. Prostate Cancer 2012. Screening and Treatment of Prostate Cancer: The 2013 Perspective
Pre-test Audience Response Screening and Treatment of Prostate Cancer: The 2013 Perspective 1. I do not offer routine PSA screening, and the USPSTF D recommendation will not change my practice. 2. In light
More informationWisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics
Wisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics In Situ Breast Cancer in Wisconsin INTRODUCTION This bulletin provides information
More informationEvidence tabel Lokaal palliatieve behandelingen
Auteurs, jaartal Mate van bewijs Studie type Follow-up Populatie (incl. steekproef-grootte) Patienten kenmerken Interventie Controle Resultaten Conclusie Opmerkingen, commentaar Hartgrink, 2002 The Netherlands
More informationTable of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation
More informationMeasure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationBreast Cancer Screening in Low- and Middle-Income Countries A Framework To Choose Screening Strategies
Breast Cancer Screening in Low- and Middle-Income Countries A Framework To Choose Screening Strategies Richard Wender, MD Session code: www.worldcancercongress.org A Five Step Framework to Guide Screening
More informationScreening Mammography for Breast Cancer: American College of Preventive Medicine Practice Policy Statement
Screening Mammography for Breast Cancer: American College of Preventive Medicine Practice Policy Statement Rebecca Ferrini, MD, Elizabeth Mannino, MD, Edith Ramsdell, MD and Linda Hill, MD, MPH Burden
More informationRandomized trials versus observational studies
Randomized trials versus observational studies The case of postmenopausal hormone therapy and heart disease Miguel Hernán Harvard School of Public Health www.hsph.harvard.edu/causal Joint work with James
More informationCardiovascular Disease in Diabetes
Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality
More informationTherapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
More informationGleason Score. Oncotype DX GPS. identified for. about surveillance. time to get sophisticated
patient: MARK SMITH PSA 6.2 Gleason Score 6 Oncotype DX GPS 8 identified for active surveillance time to get sophisticated about surveillance Accurate prediction of prostate cancer risk is needed at the
More informationRATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent
More informationAfter the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH
After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH Professor of Medicine Department of Gastroenterology Director, Viral Hepatitis Center University of California San Francisco
More informationResults of Surgery in a New Lung Institute in South Texas Focused on the Treatment of Lung Cancer
Results of Surgery in a New Lung Institute in South Texas Focused on the Treatment of Lung Cancer Lung cancer accounts for 13% of all cancer diagnoses and is the leading cause of cancer death in both males
More informationListen to your heart: Good Cardiovascular Health for Life
Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular
More informationEffective Health Care Program
Comparative Effectiveness Review Number 152 Effective Health Care Program Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer Executive Summary Background Nature and Burden of Nonmetastatic Muscle-Invasive
More informationProstate Cancer Screening: Are We There Yet? March 2010 Andrew M.D. Wolf, MD University of Virginia School of Medicine
Prostate Cancer Screening: Are We There Yet? March 2010 Andrew M.D. Wolf, MD University of Virginia School of Medicine Case #1 A 55 yo white man with well-controlled hypertension presents for his annual
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationImproving drug prescription in elderly diabetic patients. FRANCESC FORMIGA Hospital Universitari de Bellvitge
Improving drug prescription in elderly diabetic patients FRANCESC FORMIGA Hospital Universitari de Bellvitge High prevalence, but also increases the incidence. The older the patients, the higher the percentages
More informationSleeve gastrectomy or gastric bypass as revisional bariatric procedures: retrospective evaluation of outcomes. Abstract Background Methods:
Sleeve gastrectomy or gastric bypass as revisional bariatric procedures: retrospective evaluation of outcomes. Mousa Khoursheed, Ibtisam Al-Bader, Ali Mouzannar, Abdulla Al-Haddad, Ali Sayed, Ali Mohammad,
More informationCarcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology
Carcinoma of the Cervix Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Treatment Treatment Microinvasive (Stage IA1): Simple (extrafascial) hysterectomy/cone
More informationFacing Prostate Cancer Surgery? Learn about minimally invasive da Vinci Surgery
Facing Prostate Cancer Surgery? Learn about minimally invasive da Vinci Surgery The Condition: Prostate Cancer Your prostate is a walnut-sized gland that is part of the male reproductive system. The prostate
More informationCHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal
CHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal 1. STUDY TITLE: Longitudinal Assessment of Chronic Health Conditions: The Aging of Childhood Cancer Survivors 2. WORKING GROUP AND INVESTIGATORS:
More informationStudy Design Of Medical Research
Study Design Of Medical Research By Ahmed A.Shokeir, MD,PHD, FEBU Prof. Urology, Urology & Nephrology Center, Mansoura, Egypt Study Designs In Medical Research Topics Classification Case series studies
More informationPREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto
PREVENTION OF HCC BY HEPATITIS C TREATMENT Morris Sherman University of Toronto Pathogenesis of HCC in chronic hepatitis C Injury cirrhosis HCC Injury cirrhosis HCC Time The Ideal Study Prospective randomized
More informationPSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.
PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition weiss@umdnj.edu September 23, 2010 Screening: 3 tests for PCa A good screening
More information2. Background This was the fourth submission for everolimus requesting listing for clear cell renal carcinoma.
PUBLIC SUMMARY DOCUMENT Product: Everolimus, tablets, 5 mg and 10 mg, Afinitor Sponsor: Novartis Pharmaceuticals Australia Pty Ltd Date of PBAC Consideration: November 2011 1. Purpose of Application To
More informationSummary HTA. HTA-Report Summary. Introduction
Summary HTA HTA-Report Summary Antioxidative vitamines for prevention of cardiovascular disease for patients after renal transplantation and patients with chronic renal failure Schnell-Inderst P, Kossmann
More informationScreening for Prostate Cancer
Screening for Prostate Cancer It is now clear that screening for Prostate Cancer discovers the disease at an earlier and more curable stage. It is not yet clear whether this translates into reduced mortality
More informationSaturation Biopsy for Diagnosis and Staging of Prostate Cancer. Original Policy Date
MP 7.01.101 Saturation Biopsy for Diagnosis and Staging of Prostate Cancer Medical Policy Section Surgery Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date /12/2013 Return to Medical Policy
More informationESCMID Online Lecture Library. by author
Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare
More informationPROPOSAL GRADUATE CERTIFICATE ADVANCED PRACTICE ONCOLOGY SCHOOL OF NURSING TO BE OFFERED AT PURDUE UNIVERSITY WEST LAFAYETTE CAMPUS
Graduate Council Document 08-20b Approved by the Graduate Council November 20, 2008 PROPOSAL GRADUATE CERTIFICATE ADVANCED PRACTICE ONCOLOGY SCHOOL OF NURSING TO BE OFFERED AT PURDUE UNIVERSITY WEST LAFAYETTE
More informationPSA Screening for Prostate Cancer Information for Care Providers
All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationPSA Screening and the USPSTF Understanding the Controversy
PSA Screening and the USPSTF Understanding the Controversy Peter C. Albertsen Division of Urology University of Connecticut Farmington, CT, USA USPSTF Final Report 1 Four Key Questions 1. Does PSA based
More informationSignificant Heterogeneity in terms of Diagnosis and Treatment of Renal Cell Carcinoma at a Private and Public Hospital in Brazil
Clinical Urology Heterogeneity to renal cell carcinoma International Braz J Urol Vol. 37 (5): 584-590, September - October, 2011 Significant Heterogeneity in terms of Diagnosis and Treatment of Renal Cell
More informationTITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software.
SAMPLE CLINICAL RESEARCH APPLICATION ABSTRACT: TITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software. Hypothesis:
More informationPSA screening in asymptomatic men the debate continues www.bpac.org.nz keyword: psa
PSA screening in asymptomatic men the debate continues www.bpac.org.nz keyword: psa Key messages: PSA is present in the benign and malignant prostate There is currently no national screening programme
More informationEstimated GFR Based on Creatinine and Cystatin C
Estimated GFR Based on Creatinine and Cystatin C Lesley A Stevens, MD, MS Tufts Medical Center, Tufts University School of Medicine Boston MA Chronic Kidney Disease-Epidemiology Collaboration UO1 DK 053869,
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More informationAdiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced
More informationClinical Practice Guidelines
Clinical Practice Guidelines Prostate Cancer Screening CareMore Quality Management CareMore Health System adopts Clinical Practice Guidelines for the purpose of improving health care and reducing unnecessary
More informationBig Data in Healthcare: Current Possibilities and Emerging Opportunities
Big Data in Healthcare: Current Possibilities and Emerging Opportunities Andrew Bate Senior Director, Epidemiology Group Lead, Analytics 23 th March 2015 The Long Road In Developing a New Medicine Clinical
More informationHow To Decide If You Should Get A Mammogram
American Medical Women s Association Position Paper on Principals of Breast Cancer Screening Breast cancer affects one woman in eight in the United States and is the most common cancer diagnosed in women
More informationInternational Multispecialty Journal of Health (IMJH) ISSN: [2395-6291] [Vol-2, Issue-5, May- 2016]
Treatment Therapies in Renal Cell Carcinoma in elderly: A Descriptive Analysis Giorgio Maria Paolo Graziano 1, Giovanni Castelli 2, and Prof. Antonino Graziano 3 1 Department of Sciences Medical Surgery
More informationon behalf of the AUGMENT-HF Investigators
One Year Follow-Up Results from AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Heart Failure* Douglas
More informationOmega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9
Omega-3 fatty acids improve the diagnosis-related clinical outcome 1 Critical Care Medicine April 2006;34(4):972-9 Volume 34(4), April 2006, pp 972-979 Heller, Axel R. MD, PhD; Rössler, Susann; Litz, Rainer
More informationSUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:
More informationDECISION AID TOOL PROSTATE CANCER SCREENING WITH PSA TESTING
DECISION AID TOOL PROSTATE CANCER SCREENING WITH PSA TESTING This booklet is what is often called a decision aid. The goals of a decision aid are to help people better understand their medical choices
More informationDiabetes and Weight-Loss Surgery
WHITE PAPER Diabetes and Weight-Loss Surgery Treat the cause. Cure the symptom. Center of Excellence BARIATRIC SURGERY Written July 2011 Bariatric Surgery: The Cure for Type II Diabetes? For most individuals
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationThe Economic Benefit of Public Funding of Insulin Pumps in Prince Edward Island
The Economic Benefit of Public Funding of Insulin Pumps in Prince Edward Island Executive Summary Every day, Prince Edward Islanders living with type 1 diabetes take insulin to live. Many deliver insulin
More informationWhat factors determine poor functional outcome following Total Knee Replacement (TKR)?
Specific Question: What factors determine poor functional outcome following Total Knee Replacement ()? Clinical bottom line All groups derived benefit from undergoing a, reviews suggests that the decision
More informationFacing a Hysterectomy? If you ve been diagnosed with early stage gynecologic cancer, learn about minimally invasive da Vinci Surgery
Facing a Hysterectomy? If you ve been diagnosed with early stage gynecologic cancer, learn about minimally invasive da Vinci Surgery The Condition: Early Stage Gynecologic Cancer A variety of gynecologic
More informationCancer of the Cardia/GE Junction: Surgical Options
Cancer of the Cardia/GE Junction: Surgical Options Michael A Smith, MD Associate Chief Thoracic Surgery Center for Thoracic Disease St Joseph s Hospital and Medical Center Phoenix, AZ Michael Smith, MD
More informationReal World Data: How It s Used at a Medical Device Company
MD MEDICAL SAFETY Real World Data: How It s Used at a Medical Device Company Myoung Kim, Ph.D., MBA. Andrew Yoo, M.D., M.S. Epidemiology and Health Informatics Medical Devices Johnson & Johnson May 29,
More informationSix Degrees of Separation No More: Using Data Linkages to Improve the Quality of Cancer Registry and Study Data
Six Degrees of Separation No More: Using Data Linkages to Improve the Quality of Cancer Registry and Study Data Prepared for the 138th Annual Meeting of the American Public Health Association Denver, CO
More informationGuide to Biostatistics
MedPage Tools Guide to Biostatistics Study Designs Here is a compilation of important epidemiologic and common biostatistical terms used in medical research. You can use it as a reference guide when reading
More informationThe Women s Health Initiative: The Role of Hormonal Therapy in Disease Prevention
The Women s Health Initiative: The Role of Hormonal Therapy in Disease Prevention Robert B. Wallace, MD, MSc Departments of Epidemiology and Internal Medicine University of Iowa College of Public Health
More informationThe Economic Benefit of Public Funding of Insulin Pumps in. New Brunswick
The Economic Benefit of Public Funding of Insulin Pumps in New Brunswick Introduction Diabetes is a chronic, often debilitating and sometimes fatal disease, in which the body either cannot produce insulin
More informationIndividual Prediction
Individual Prediction Michael W. Kattan, Ph.D. Professor of Medicine, Epidemiology and Biostatistics, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Chairman, Department
More information